Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also developing newer medicines that will improve its financial results. 10 stocks we ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $82.5 billion by ...

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.

Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a biotech giant, have been southbound over the past two years as the ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the stocks Jim Cramer was recently asked about. A caller asked if the ...

Here’s why we believe Regeneron Pharmaceuticals (REGN) stock merits attention as a value addition. Currently, it is trading almost 44% lower than its 1-year peak and is also priced at a PS multiple ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials of itepekimab in chronic obstructive pulmonary disease (COPD) patients.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $750.0 for Regeneron Pharmaceuticals, spanning the ...

This was the stock's fifth consecutive day of losses.